Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Han-Chung, Hamzah, Hamizun, Leong, Melody Pui-Yee, Md Yusof, Hadri, Habib, Omar, Zainal Abidin, Shahidee, Seth, Eryse Amira, Lim, Siong-Meng, Vidyadaran, Sharmili, Mohd Moklas, Mohamad Aris, Abdullah, Maizaton Atmadini, Nordin, Norshariza, Hassan, Zurina, Cheah, Pike-See, Ling, King-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884429/
https://www.ncbi.nlm.nih.gov/pubmed/33589712
http://dx.doi.org/10.1038/s41598-021-83222-z

Ejemplares similares

Ejemplares similares